Ensysce Biosciences (ENSC) Income from Non-Controlling Interests (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Income from Non-Controlling Interests of -$166.0 for Q2 2025, down 124.32% quarter-over-quarter from -$74.0 in Q1 2024.
Ensysce Biosciences (ENSC) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Income from Non-Controlling Interests for 6 consecutive years, with -$166.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Income from Non-Controlling Interests changed N/A year-over-year to -$166.0; the TTM figure through Sep 2025 stood at -$166.0 (up 84.02% YoY), while the FY2024 annual figure was -$74.0, up 99.44% from the prior year.
- Income from Non-Controlling Interests slipped to -$166.0 in Q2 2025 per ENSC's latest filing, from -$74.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $12226.0 in Q4 2022 and bottomed at -$35948.0 in Q3 2021.
- Historically, Income from Non-Controlling Interests has averaged -$7930.3 across 5 years, with a median of -$2588.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests jumped 5813.08% — and 2023, when it sank 2265.38%.
- Ensysce Biosciences' Income from Non-Controlling Interests stood at -$214.0 in 2021, then surged by 5813.08% to $12226.0 in 2022, then sank by 107.89% to -$965.0 in 2023, then soared by 92.33% to -$74.0 in 2024, then slumped by 124.32% to -$166.0 in 2025.
- Business Quant data shows ENSC's Income from Non-Controlling Interests at -$166.0 in Q2 2025, -$74.0 in Q1 2024, and -$965.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -166.00 |
| Mar 31, 2024 | -74.00 |
| Dec 31, 2023 | -965.00 |
| Sep 30, 2023 | -1,235.00 |
| Jun 30, 2023 | -7,060.00 |
| Mar 31, 2023 | -3,941.00 |
| Dec 31, 2022 | 12,226.00 |
| Sep 30, 2022 | -21,492.00 |
| Jun 30, 2022 | -26,309.00 |
| Mar 31, 2022 | 182.00 |
| Dec 31, 2021 | -214.00 |
| Sep 30, 2021 | -35,948.00 |
| Jun 30, 2021 | -22,067.00 |
| Mar 31, 2021 | -3,961.00 |
| Dec 31, 2020 | -195,655.00 |
| Sep 30, 2020 | -20,014.00 |
| Jun 30, 2020 | -1,976.00 |